ArticleESMO open2022

Validation of the Meet-URO score in patients with metastatic renal cell carcinoma receiving first-line nivolumab and ipilimumab in the Italian Expanded Access Program.

S E Rebuzzi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.